DocumentsDate added
Original article
Oluwatosin K. Shittu1, Bashir Lawal1,*, Asmau N. Abubakar1, Eustace B. Berinyuy2, ,Busari B. Musa3, Ibrahim A Olalekan4.
Affiliation:
1Tropical Disease Research Unit, Department of Biochemistry, Federal University of Technology, P.M.B.65, Minna, Nigeria
2Faculty of medicine and Biomedical Science, University of Yaounde 1, Cameroon
3Centre for Genetic Engineering and Biotechnology, Global Institute for Bioexploration Unit, Federal University of Technology Minna, Nigeria.
4Forestry Technology Department Federal College of Wild Life Management, New Bussa, Niger State, Nigeria
The name of the department(s) and institution(s) to which the work should be attributed:
1.Tropical Disease Research Unit, Department of Biochemistry, Federal University of Technology, P.M.B.65, Minna, Nigeria
2.Faculty of medicine and Biomedical Science, University of Yaounde 1, Cameroon
3. Centre for Genetic Engineering and Biotechnology, Global Institute for Bioexploration Unit, Federal University of Technology Minna, Nigeria.
4. Forestry Technology Department Federal College of Wild Life Management, New Bussa, Niger State, Nigeria
Address reprint requests to
* Bashir Lawal.
Department of Biochemistry, Tropical Disease Research Unit, Federal University of Technology, P.M.B. 65, Minna, Nigeria.
Phone no: +234 -8165112378
Article citation: Shittu OK, Lawal B, Abubakar AN, Berinyuy BE, Busari MB, Ibrahim AO. Toxicological implications of methanol extract from Nigerian Bee propolis on some selected rat tissues. J Pharm Biomed Sci. 2015; 05(07):524-531. Available at www.jpbms.info
ABSTRACT: Objectives: The present study investigates the effects of Nigerian bee propolis on some biochemical indices in some selected rat tissues. Methods: A total of Fifteen wistar rats were grouped into 3(A-C) of 5 rats each. Group A rats serve as control groups and received 0.5ml of DMSO, while groups B and C received 300 and 600 ml/kg of methanol extract of honey bee propolis respectively, for 21 days through oral route.
Results: The extract significantly increased (p<0.05) the Spleen and small intestine ALT activities, kidney and small intestine AST activities, kidney ALP activities as well as the level of total protein in Liver and spleen of bee propolis treated rats. In contrast, the Liver and spleen AST activities, and liver ALP activities decrease significantly (p<0.05) in bee propolis treated rats when compared with their corresponding controls. However, the spleen and small intestine ALP activities, level of kidney and small intestine total protein as well as ALT activities in the kidney of bee propolis treated rats compared well (p>0.05) with the normal value at the extract doses studied. The computed liver, kidney, and small intestine body weight ratios of rats treated with the extract does not differ(p>0.05) with those of the control rats, however, increase in spleen/body weight in propolis treated rats than the control group was observe.
Conclusion: The chronic administration of methanol extracts of bee propolis altered the normal values of some biochemical parameters in rat organs. Clinical application of the bee propolis should therefore be carefully controlled as it chronic administration may be relatively unsafe for the integrity of organs.
KEYWORDS: Propolis; Liver; Kidney; Spleen; Small intestine; Biomarker enzyme; Total proteins.
REFERENCES
1. Bashir L, Shittu OK, Sani S, Busari MB, Adeniyi KA. African Natural Products with Potential Antitrypanosoma Properties: A Review. International Journal of Biochemistry Research and Review 2015a; 7(2): 45-79.
2.Gurib-Fakim A. Medicinal plants: Traditions of yesterday and drugs of tomorrow. Molecular Aspects of Medicine 2006; 27:1–93.
3.Taylor JLS, Rabe T. McGaw LJ, Jäger AK, van Staden J. Towards the scientific validation of traditional medicinal plants. Plant Growth Regulation. 2001,34:23–37.
4.Oyewo EB, Fakunle PB. Safety Concerns Of The Repeated Administration Of Yoyo Bitters In Male Wistar Rats. International Journal of Pharmacy and Pharmaceutical Sciences 2013.5(3); 323-332.
5.Salau AK, AkanjiMA, Yakubu, MT.Safety Evaluation of Aqueous Extract of Crateva adansonii Leaves on Selected Tissues of Rats. Fountain J of Nat Appl Scie 2013; 2(1): 17 – 28.
6.Anofi OTA, Latifat OO,, Musa TY.Toxicity profile of ethanolic extract of Azadirachta indica stem bark in male Wistar rats. Asian Pac J Trop Biomed 2012; 2(10): 811-817.
7.Sforcin JM, Bankova V: Propolis: is there a potential for the development of new drugs? J Ethnopharmacol 2011;133:253–260.
8.Sforcin J.M. Propolis and the Immune System: a review, Journal of Ethnopharmacology 2007;113:1-14.
9.Watanabe MA, Amarante MK, Conti BJ, Sforcin JM. Cytotoxic constituents of propolisinducing anticancer effects: a review.Journal of Pharmacy and Pharmacology 2011; 63(11):1378-1386.
10.Guimarães NS, Mello JC, Paiva JS, Bueno PC, Berretta AA, Torquato RJ, Nantes IL, Rodrigues T. Baccharis dracunculifolia, the main source of green propolis, exhibits potent antioxidant activity and prevents oxidative mitochondrial damage. Food Chemistry Toxicology 2012; 50 (3-4):1091-1097.
11.Basista-Sołtys K, Allergy to Propolis in Beekeepers-A Literature Review. Occup Med Health Aff, 2013;1(1):1-3
12.Institute of laboratory animal resources, commission on life sciences, National Research Council. Occupational Health and Safety in the Care and Use of Research Animals, Washington, DC: National Academy Press; 1997.
13.Shittu OK, Olayemi IK, Omalu ICJ, Adeniyi AK. Antiplasmdial properties of methanolic extract of Muscadomestica maggot on P. berghei infected mice.International journal of biology pharmacy and allied science 2013; 2(5): 1064-1070.
14.Yakubu MT, Musa IF.Liver and Kidney Functional Indices of Pregnant Rats Following the Administration of the Crude Alkaloids from Sennaalata (Linn. Roxb) Leaves. Irani Jour Toxicol 2012;6:16, 615-625.
15.Tietz NW. Clinical Guide to Laboratory Tests. 3rd Edition, 1995, Pp. 286 – 288.
16.Reitman S, Frankel SA. Colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American J of Clin Pathol 1957; 28:56-63.
17.Gornall AC, Bardawill CJ, David MM. Determination of serum protein by means of biuret reaction. Journal of Biol Chem 1949; 177:751-756.
18. Bashir L, Shittu O.K , Busari M.B, Sani S. and Aisha MI. Safety Evaluation of Giant African land Snails (Archachatinamarginata) Haemolymph on Hematological and Biochemical Parameters of Albino Rats. J. Adva. Med. Pharm.Sci 2015b,3(3):122-130.
19.Statistical Package for Social Sciences for Windows (SPSS) 14.0 .Computer Program, MS. For Windows, Version 14.00, SPSS Inc., Chicago. 2005 Release 14.0. http://www.Spss.com.
20.Ashafa AOT, Sunmonu TO, Afolayan AJ.Effects of leaf and berry extracts of Phytolacca dioica L. on haematological and weight parameters of Wistar rats. African Journal of Pharmacy and Pharmacology 20115(2):150-154.
21.Olaoluwa TA, Odutola O, Olugbenga OA, Funmilayo DO, Sunday OO, Afolayan AJ.Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Activities in Selected Tissues of Rats Fed on Processed Atlantic Horse Mackerel (Trachurus trachurus) Advances in Bioscience and Biotechnology 2015; 6:139-152.
22.Lawal B, Shittu OK, Ossai PC, Abubakar AN, Ibrahim AM. Antioxidant Activities of Giant African Snail (Achachatina maginata) Haemolymph against CCl4- Induced Hepatotoxicity in Albino Rats. B. j.pharmal res 2015c.6(3): 141-154.
23.Oyewo EB, Akanji MA, Iniaghe MO and Fakunle PB. Toxicological Implications of Aqueous Leaf Extract of Andrographis paniculata in Wistar Rat. Nature and Science 2012; 10(2):91-108.
24.Adeyemi OS, Fambegbe M, Daniyan OR and Nwajei I. Yoyo Bitters, a polyherbal formulation influenced some biochemical parameters in Wistar rats. J Basic Clin Physiol Pharmacol 2012;12;0 (0):1-4.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2015 Shittu OK, Lawal B, Abubakar AN, Berinyuy BE, Busari MB, Ibrahim AO. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Jyoti Bala*,Kumar Saurabh,Veena Singh Ghalaut, Yuthika Aggrawal
Affiliation:
*Department of Biochemistry, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biochemistry, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
Address reprint requests to
* Dr. Jyoti Bala,
D-2, New Bharat, Nagar, Bhiwani, Haryana,India
Article citation: Bala J, Saurabh K, Ghalaut VS, Aggrawal Y. Study the levels of folic acid, vitamin B12 and ferritin in thalassemia. J Pharm Biomed Sci. 2015; 05(07):539-541. Available at www.jpbms.info
ABSTRACT: Objective: To estimate the levels of folic acid, vitamin B12 and ferritin in thalassemic children.
Material and Methods: This study was carried out in the Department of Biochemistry in PGIMS, Rohtak. Thirty children with the confirmed diagnosis of thalassemia were enrolled in the study group and thirty healthy age and sex matched children were included in the control group. Estimation of serum ferritin, folic acid and vitamin B12 were done by ADVIA Centaur CP autoanalyzer by chemiluminescence immunoassay.
Results: Study group showed a decrease in serum folic acid and vitamin B12 levels with mean value of 8.91 ±1.04 ng/mL and 241.33± 29.28 pg/mL respectively as compared to control group was 12.23±1.31 ng/mL and 419.63±58.47 pg/mL (p<0.001) whereas increased concentration of ferritin with mean value of 3466.75± 2028.96 ng/mL in study group as compared to control group was 176.70±11.63 and was statistically highly significant (p<0.001).
Conclusion: The present study found a significant decrease of vitamin B12, folic acid and increased ferritin in children with thalassemia. Biochemical screening of these parameters is of paramount importance in thalassemia patients in paediatric age group. Also, there is an absolute need for further studies to understand the mechanism of relationship between serum ferritin, Vitamin B12 and folic acid in these patients.
KEYWORDS: Thalassemia; Ferritin; vitamin B12; Folic acid.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
REFERENCES
1.Maheshwari M, Sadhna A, Kabra M, Menon PSN. Carrier screening and prenatal diagnosis of Beta-Thalassemia. Ind Paediatr 1999;36:1119-25.
2.Tyagil S, Kabra M, Tandon N, Saxena R, Pati HP, Choudhary VP. Clinico-Haematological Profile of Thalassemia Intermedia patients. Int J Hum Genet 2003;3:251-8.
3.Granier T, Langlois d Estaintot B, Gallois B,Santambrogio P, et al. Structural description of the active sites of mouse L-chain ferritin at 1.2 A resolution. J Bio In org Chem 2003;88:105-11.
4.Ryan GM, Torelli J. Beyond cholesterol: 7 life-saving heart disease tests that your doctor may not give you. New York: St. Martin’s Griffin; 2005.
5.Kennedy A, Kohn M, Lammi A, Clarke S. Iron status and hematoloical changes in adolescent female inpatients with anorexia nervosa. J Paediatric Child health 40;430-2
6.Alfrey CP. Serum ferritin assay. CRC Crit Rev Clin Lab Sci 1978;9:179-208.
7.McNeely MDD. Folic acid assay. In Kaplan LA, Pesce AJ,(eds). Clinical Chemistry. St. Louis: CV Mosby, 1984:1402-6
8.Allen RH. Clinical role and current status of serum cobalamine (vitamin B12) assays. Ligand Quaterly 1981;4;37-44.
9.Tamagnini GP, Lopes MC, Castenheira ME, Wainscoat JS, Wood WG. β- thalassemia-Portguise type: Clinical, haematologial and molecular studies of a newly defined form of β thalassemia. Br J Haematol 1983;54:189- 200.
10.Werbach MR. Nutritional Imbalances in Anemia. Townsend Letter 2008:119-20.
11.Cohen AR. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am. 1987;1:521–44.
12.Borgna-Pignatti C, Rugolotto S, De Stefano. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2015 Bala J,Saurabh K,,Ghalaut VS,Aggrawal Y. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Santosh Kumar Sahu*,M.S
Affiliation:
Nilratan Sircar MC & H, Kolkata, India
The name of the department(s) and institution(s) to which the work should be attributed:
Nilratan Sircar MC & H, Kolkata, India
Address reprint requests to
* Dr.Santosh Kumar Sahu.
M.S.Orthopaedics, Nilratan Sircar MC & H, Kolkata, India
Article citation: Sahu SK. Scapular osteochondroma: A rare presentation. J Pharm Biomed Sci. 2015; 05(07):589-593. Available at www.jpbms.info
ABSTRACT: We here with present a case of osteochondroma arising from the from scapula in a 4yrs child presented with huge swelling over the scapular region.Since 1 yr of age the swelling was gradually increasing in size but painless & shoulder movement terminally restricted. The lesion was free from chest wall. There was no h/o- fever, cough, weight loss or any other constitutional symptoms or any neurovascular deficit. There was no h/o trauma.MRI showed a 7.5x6x5 cm, mushroom shaped, pedunculated mass arising from inferior angle & lateral margin of left scapula, lung fields were clear, the lesion was free from chest wall & the surrounding soft tissue density was normal. After thorough investigation, en bloc resection of tumor was done with partial scapulectomy and sent for histopathological examination. The diagnosis of osteochondroma was established on HPE. No residual deficit was found post-operatively. Patient was relieved of the symptoms and is now under follow-up.
KEYWORDS: Osteochondroma of scapula.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2015 Sahu SK. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article
Divya Jaggi¥*, Anjani Pathak¥, Jaya Dixit¥, Indira Chaturvedi¥, Kopal Goel±
Affiliation:
¥Department of Periodontology, ±Department of Prosthodontics, Faculty of Dental Sciences, King George’s Medical University, Lucknow-226003, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Periodontology, Faculty of Dental Sciences, King George’s Medical University, Lucknow-226003, India
Address reprint requests to
* Dr. Divya Jaggi.
Senior Resident, Department of Periodontology, Faculty of Dental Sciences, King George’s Medical University, Lucknow-226003, India
Article citation: Pathak A, Jaggi D, Dixit J, Chaturvedi I, Yadav K. Pharmacologic agents in periodontics: A review. J Pharm Biomed Sci. 2015;05(07):609-620. Available at www.jpbms.info
ABSTRACT: The fundamental aspect of the treatment is that the clinician should constantly update his knowledge on the drugs being administered during the course of treatment and their interactions. This article focuces on the current pharmacological agents being used in the management of periodontal conditions. All drug sensitivities and allergies should be reviewed prior to incorporating pharmacological agents into a patient’s treatment regimen. Recent advances in technology have led to a constant drive to develop novel strategies for the treatment of periodontal diseases. The future is promising in the areas of vaccines but more research is needed.
KEYWORDS: Pharmacology; Therapeutics; Periodontics.
REFERENCES
1.Bennett, C.R. (1984). Monheim’s local anesthesia and pain control in dental practice 7th ed. St. Louis, Mosby, pp.129.
2.Lang NP, Lindhe J. Clinical periodontology and implant dentistry. 5th ed. Oxford: Blackwell, Munksgaard;2012.
3.Katherine E. Wilson, Matthew L. Dorman, Paul A. Moore & Nicholas M. Girdler. Pain control and anxiety management for periodontal Therapies. Periodontology 2000 2008; 846: 42–55.
4.Martin MD, Ramsey DS, Whitney C, Fiset L, Weinstein P. Topical anesthesia: differentiating the pharmacological and psychological contributions to efficacy. Anesth Prog 1994;41:40–47.
5.Meechan JG. Intraoral topical anesthesia. Periodontology 2000 2008;46:56-79.
6.Hill Fanzca JS. Preoperative application of EMLA cream and the temporomandibular arthrocentesis procedure. Br J Oral Maxillofac Surg 2007;45: 342–343.
7.Holst A, Evers H. Experimental studies of new topical anaesthetics on the oral mucosa. Swed Dent J 1985; 9: 185–191.
8.Svensson P, Petersen JK . Anesthetic effect of EMLA occluded with oradhesive oral bandages on oral mucosa. A placebo-controlled study. Anesth Prog 1992;39:79–82.
9.Friskopp J, Nilsson M, Isacsson G. The anesthetic onset and duration of a new lidocaine ⁄ prilocaine gel intrapocket anesthetic (Oraqix) for periodontal scaling ⁄ root planing. J Clin Periodontol 2001;28:453–458.
10.Yagiela, J.A., Dowd, F.J., Neidle, E.A. Pharmacology and therapeutics for Dentistry 5th edn. St Louis: Mosby, 2004.
11.British National Formulary. Royal Pharmaceutical Society of Great Britain, 20-5 Prescribing in Dental Practice. London: BMA and Royal Pharmaceutical Society of Great Britain,2006.
12.Mohan M, Gupta A, Shenoy V, Parolia A. Pharmacological Agents in Dentistry: A Review. British Journal of Pharmaceutical Research 2011;1(3):66-87.
13.Poveda-Roda, R., Bagán, J.V., Jiménez-Soriano, Y., Gallud-Romero, L. Use of nonsteroidalantiinflammatory drugs in dental practice - A review. Med. Oral Patol. Oral Cir. Bucal 2001;12: E10-18.
14.Dionne RA, McCullagh L. The S(+) isomer of ibuprofen suppresses plasma 3-endorphin coincident with analgesia in humans. Clin Pharmacol Ther 1998;63:694-701.
15.Dionne R, Cooper SA. Evaluation of preoperative ibuprofen on postoperative pain after impaction surgery. Oral Surg Oral Med Oral Pathol 1978;45:851-856.
16.Dionne R, Berthold C. Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry. Crit Rev Oral Biol Med 2001;12(4):315-330.
17.Felpel, L.P. A review of pharmacotherapeutics for prosthetic Dentistry: Part II. J Prosthet Dent 1997;77: 293-305.
18.Mehlisch, D.R.The efficacy of combination analgesic therapy in relieving dental pain. J. Am. Dent. Assoc 2002;133:861-871.
19.Ong KS & Seymour RA. An evidence-based update of the use of analgesics in dentistry. Periodontology 2000 2008;46:143–164.
20.Seymour RA & Hogg SD. Antibiotics and Chemoprophylaxis. Periodontology 2000 2008; 46:80–108.
21.Paluzzi RG. Antimicrobial prophylaxis for surgery. Med Clin North Am 1993;77:427–441.
22.Mombelli A, Schmid B , Rutar A , Lang NP. Persistence patterns of P.gingivalis, A. actinomycetemcomitans, P. intermedia after mechanical therapy of periodontal disease. Journal of Periodontology 2000;71:14-21.
23.Zambon J.J, Reynolds H.S, Slots J. Black pigmented Bacteroides spp. in the human oral cavity. Infection and Immunity 1981;32:198-203
24.Muller HP, Lang DE & Muller RF.Failure of adjunctive minocycline-HCl to eliminate A. actionmyctemcomitans. Journal of Clinical Periodontology 1993;20:498-504.
25.Van Winkelhoff , A.J. & Winkel E.G.Microbiological diagnostics in periodontics. Biological significance and clinical validity. Periodontology 2000 2005;39:40-52.
26.Newman M, Takei H, Klokkevold P, Carranza F.Clinical Periodontology.11th edition. St Louis, Elsevier,2012.
27.Mc Bee, W.L., Koerner, K.R. Review of Hemostatic agents used in Dentistry. Dent Today 2005;24:62-65.
28.Pallasch TJ .Antifungal and antiviral chemotherapy. Periodontology 2000 2002;28: 240–255.
29.Glick M, Siegel MA. Viral and fungal infections of the oral cavity inimmunocompetent patients. Infect Dis Clin NorthAm 1999;13:817–831.
30.Muzyka BC, Glick M. A review of oral fungal infections and appropriate therapy. J Am Dent Assoc 1995;126:63–72.
31.Slots J. Oral viral infections of adults. Periodontol 2000 2009;49:60–86.
32.Sunde PT, Olsen I, Enersen M, Grinde B . Patient with severe periodontitis and subgingival Epstein–Barr virus treated with antiviral therapy. J Clin Virol 2008;42: 176–178.
33.Birek C. Herpes virus-induced diseases: oral manifestations and current treatment options. Calif Dent Assoc J 2000;28:911–921.
34.Evans RT, Klausen B, Genco RJ. Immunization with fimbrial protein and peptide protects against Porphyromonas gingivalis-induced periodontal tissue destruction. Adv Exp Med Biol 1992;327:255-262.
35.Booth V, Ashley FP, Lehner T Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Infect Immun. 1996 Feb;64(2):422-7.
36.SC Ng, AL Hart, MA Kamm, AJ Stagg, SC Knight. Mechanisms of Action of Probiotics: Recent Advances. Inflamm Bowel Dis 2009;15:300‐310.
37.Meurman JH, Stamatova I. Probiotics: contributions to oral health. Oral Dis 2007;13(5):443-451.
38.Mackay AD, Taylor MB , Kibbler CC, Hamilton- Miller JM..Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1995;5:290-292.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2015 Pathak A, Jaggi D, Dixit J, Chaturvedi I, Yadav K. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.